eligibility_summary
Adults (≥18) with confirmed multiple myeloma (IMWG) or CD19+ lymphoproliferative disorder (WHO 2016). Must provide informed consent, agree to bone marrow aspirate, hair follicle, saliva/buccal samples, and return for follow-up. Exclude if ineligible for CAR-T therapy or if diagnosed with a myeloid neoplasm before CAR-T.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial type: Supportive-care/mechanism study after CAR-T. Interventions: no therapeutic drug, procedures include bone marrow aspirations, hair/buccal/saliva biospecimen collection, genetic testing with counseling, electronic health record review, and scheduled follow-up. Therapy under study context: prior CAR-T (cellular immunotherapy, autologous T cells engineered with a chimeric antigen receptor) used for MM or CD19+ LPD. Mechanism of CAR-T: CAR engagement activates T-cell cytotoxicity against antigen-expressing malignant cells (CD19 for LPD, disease-appropriate antigen for MM), which may contribute to prolonged cytopenias. Cells/pathways targeted: CAR-T targets malignant B-lineage/plasma cells, the study interrogates hematopoietic stem/progenitor and myeloid lineages in bone marrow, assessing germline/somatic variants and baseline transcriptomic signatures linked to clonal vs non-clonal cytopenia and evolution to myeloid neoplasms.